A tissue-on-a-chip platform for systems-level studies of ALS pathology and drug screening

Información del proyecto

Als-on-a-chip

Identificador del acuerdo de subvención: 658850

DOI

10.3030/658850

Proyecto cerrado

Fecha de la firma de la CE 9 Abril 2015

Fecha de inicio 30 Septiembre 2015

Fecha de finalización 29 Septiembre 2017

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 164 653,20

Aportación de la UE

€ 164 653,20

Coordinado por

IDRYMA TECHNOLOGIAS KAI EREVNAS
Greece

Objetivo

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease, which affects approximately 2 per 100000 people. Currently, there is no ALS treatment. The main tool for preclinical ALS studies is the hSOD1G93A mouse. However, despite promising results in this model, all candidate drugs failed in clinical trials. These failures have been partly attributed to differences in the physiology of human and mice nerve cells, and the inability of the established drug design approach to block ALS pathology. There is urgent need for new tools that will complement this mouse model, improve understanding of ALS pathology, and suggest better leads for clinical trials.
The objective of the proposed study is to develop a tissue-on-a-chip platform for systems-level studies of ALS pathology and drug screening. The system is built around a novel thin porous scaffold, where systems of normal or ALS-type mouse and human motor neurons will be cultured inside an appropriate 3D ECM analog, and their response (intracellular signaling, cell processes, cell-cell communication) to stimuli panels in the presence of drugs will be quantified via high-throughput proteomics and fluorescent imaging. Acquired data will be interpreted by modifications of state-of-the-art system biology tools.
The outcomes of the proposed research can lead to new ALS treatments by identifying new drug targets (via mechanistic description of ALS pathology), and by developing better ways to evaluate candidate drugs before clinical trials (via comparing drug response in human and mouse cells). Results can be translated to other neurodegenerative diseases. Finally, the proposal offers an opportunity to a promising researcher to relocate from MIT to Greece, collaborate with a leading neurobiology lab in a world-class environment and a systems pharmacology SME, and translate his research via two startup companies. The host envisions the opportunity for a tenure-track faculty position for the experienced researcher.

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › medicina básica › farmacología y farmacia › descubrimiento de fármacos
• ciencias médicas y de la salud › medicina básica › neurología › demencia › alzheimer
• ciencias médicas y de la salud › biotecnología médica › tecnologías celulares › células madre
• ciencias médicas y de la salud › medicina básica › patología
• ciencias médicas y de la salud › medicina básica › neurología › esclerosis lateral amiotrófica

Programa(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions PROGRAMA PRINCIPAL
  
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
  

Tema(s)

• MSCA-IF-2014-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF)
  

Régimen de financiación

MSCA-IF-EF-RI - RI – Reintegration panel

Convocatoria de propuestas

H2020-MSCA-IF-2014

Coordinador

IDRYMA TECHNOLOGIAS KAI EREVNAS

• Aportación neta de la UEn: € 164 653,20
• Dirección: N PLASTIRA STR 100 ; 70 013 IRAKLEIO ; Grecia
• Región: Νησιά Αιγαίου › Κρήτη › Ηράκλειο
• Tipo de actividad: Research Organisations
• Coste total: € 164 653,20